Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.6 (
chymopapain
)
407
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Agglutination studies with 6 plant lectins indicated that the unaltered surface coat of Trypanosoma equiperdum isolated from rat blood lacks the carbohydrate molecules preferentially bound by these proteins. However, trypsin, pronase,
chymopapain
, or papain treatments exposed the binding sites for Concanavalin A and the phytohemagglutinins M and P and trypsinized cells were attached to Concanavalin A immobilized on agarose beads. Lipolytic, amylytic, and other proteolytic enzymes or other agents did not reduce or induce lectin agglutination and wheat germ, Anti A, and Anti H lectins did not clump the trypanosomes under any of the conditions employed. Carbohydrate residues resembling D-mannose or n-acetyl-D-
galactosamine
are therefore within the surface coat of T. equiperdum or on the cell membrane underneath it. The results are contrasted with the lectin induced agglutination of other parasite species and mammalian cells.
...
PMID:Lectin binding by trypanosoma equiperdum. 84 43
In the adult mongrel dog, in vivo injection of
chymopapain
into the intervertebral disc resulted, at two weeks, in disc space narrowing. However, [35S]sulfate labeling and proteoglycan characterization demonstrate that the nucleus retains the ability to synthesize proteoglycans, although they were degraded rapidly by residual proteolytic activity. Three months following
chymopapain
treatment, the intervertebral dog disc shows that an increase in disc height, return of nuclear material, and proteoglycan aggregate is present. At six months following
chymopapain
treatment, proteoglycans of similar characteristics to normal canine intervertebral disc are identified with a glucosamine/
galactosamine
ratio approaching normal values. Biomechanically, the short-term (30-120 minutes) in vitro effects of
chymopapain
appear to be the same as the carrier causing increased disc height, stiffness values, and creep rates. In the vivo study, after three weeks,
chymopapain
-injected discs had significant reductions in disc height and compressive stiffness, but the creep rate was increased substantially. However, at three months postinjection, these biomechanical properties began to reverse and approached those of the uninjected controls. The observations reported in this study suggest that
chymopapain
has a profound but reversible effect on normal canine intervertebral disc. The radiographic narrowing of the intervertebral disc following
chymopapain
injection correlates with loss of proteoglycan content, structure, and biomechanical properties. The restoration of normal disc height following
chymopapain
injection is explained by reconstitution of normal intervertebral disc. EDTA and cysteine used alone have no discernable in vivo enzymatic effect on intervertebral disc proteoglycan biochemistry. Chemonucleolysis with
chymopapain
would appear less likely to alter permanently proteoglycan biochemistry and the biomechanical properties of the disc than surgical excision in experimental animals.
...
PMID:Chymopapain, chemonucleolysis, and nucleus pulposus regeneration. A biochemical and biomechanical study. 642 41